Patents Examined by Christina Y. Chan
  • Patent number: 7060796
    Abstract: The present invention provides a purified, homogeneous plant enzyme that adds a ?-1,2-linked xylose to the ?-linked mannose on the N-linked oligosaccharides of storage glycoproteins. This ?1,2-xylosyltransferase was purified from the microsomal fraction of soybean cells approximately 51,000-fold. Also provided is an antibody recognizing this ?1,2-xylosyltransferase.
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: June 13, 2006
    Assignee: The Board of Trustees of the University of Arkanas
    Inventors: Alan D. Elbein, Gary A. Bannon
  • Patent number: 6737059
    Abstract: Disclosed are methods for the alleviation of symptoms associated with inflammatory disease states, and more particularly to the inhibition of inflammatory disease processes associated with the multiple sclerosis disease, by adminstering to a patient a phamaceutically effective amount of mAb 23F2G or an antibody that competes with mAb 23F2G for binding to LFA-1.
    Type: Grant
    Filed: November 3, 1994
    Date of Patent: May 18, 2004
    Assignees: Board of Regents of the University Washington, ICOS Corporation
    Inventor: Lynn M. Rose
  • Patent number: 6719976
    Abstract: The present invention provides a monomolecular multi-epitope peptide prepared by binding T cell epitope regions derived from different allergen molecules with each other. A peptide-based immunotherapeutic agent containing an effective amount of the multi-epitope peptide can treat a wide range of allergic diseases.
    Type: Grant
    Filed: September 9, 1998
    Date of Patent: April 13, 2004
    Assignee: Meiji Milk Products Co., Ltd.
    Inventors: Toshio Sone, Akinori Kume, Kazuo Dairiki, Akiko Iwama, Kohsuke Kino
  • Patent number: 6531130
    Abstract: Compositions and methods are provided for the treatment of demyelinating autoimmune disease. Therapeutic doses are administered of an ordered peptide comprising a repeated motif {SEQ ID NO: 1} [1E2Y3Y4K]n, where n is from 2 to 6. Some specific peptides of interest include those having the sequence {SEQ ID NO: 4} EYYKEYYKEYYK. The peptide may consist only of the ordered repeats, or may be extended at either termini by the addition of other amino acid residues. For therapy, the peptides may be administered topically or parenterally, e.g. by injection at a particular site, including subcutaneously, intraperitoneally, intravascularly, or the like or transdermally, as by electrotransport. In a preferred embodiment, subcutaneous injection is used to deliver the peptide. The subject methods are used for prophylactic or therapeutic purposes. The compositions of the invention may also contain other therapeutically active agents, e.g. immunosuppressants, &bgr;-interferon, steroids, etc.
    Type: Grant
    Filed: June 28, 2000
    Date of Patent: March 11, 2003
    Assignee: The Board of Trustees of the Leland Stanford University
    Inventors: Lawrence Steinman, Pedro José Ruiz
  • Patent number: 6500923
    Abstract: The present invention relates to a dermatomyositis-specific auto-antigen, a DNA encoding it and a process for the preparation thereof as well as its use.
    Type: Grant
    Filed: September 22, 1998
    Date of Patent: December 31, 2002
    Assignee: Privates Institut fur Immunologie und Molekulargenetik GmbH
    Inventors: Hans Peter Seelig, Manfred Renz
  • Patent number: 6488932
    Abstract: The invention involves the reception of particular nonapeptides by HLA molecules. The nonapeptides are derived from expression products of the MAGE gene family. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
    Type: Grant
    Filed: December 12, 1995
    Date of Patent: December 3, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurquin, Catia Traversari
  • Patent number: 6485955
    Abstract: Disclosed herein are the cDNA and polypeptide sequences of a novel cytoplasmic post-prolyl dipeptidase, QPP. QPP is expressed in T-cells and in neurons, and functions to protect quiescent cells from apoptotic death. Therefore, QPP can be used as a therapeutic to inhibit apoptotic cell death and as a target in screening for compounds that modulate cell death.
    Type: Grant
    Filed: September 1, 1999
    Date of Patent: November 26, 2002
    Assignee: The Trustees of Tufts University
    Inventors: Brigitte T. Huber, Robert H. Underwood
  • Patent number: 6472368
    Abstract: Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a motif. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.
    Type: Grant
    Filed: July 9, 1999
    Date of Patent: October 29, 2002
    Assignee: Adherex Technologies, Inc.
    Inventors: Patrick Doherty, Orest W. Blaschuk, Barbara J. Gour
  • Patent number: 6448035
    Abstract: A new family of immunoreceptor molecules of the immunoglobulin superfamily, (LIR) polypeptides is described. Disclosed are sequences encoding LIR family members and their deduced amino acid sequences, polypeptides encoded by DNA that hybridize to oligonucleotide probes having defined sequences, processes for producing polypeptides of the LIR family, and antagonistic antibodies to LIR family members. LIR family members can be used to treat autoimmune diseases and disease states associated with suppressed immune function.
    Type: Grant
    Filed: April 24, 1997
    Date of Patent: September 10, 2002
    Assignee: Immunex Corporation
    Inventor: David J. Cosman
  • Patent number: 6447765
    Abstract: The field of the invention is generally related to pharmaceutical agents useful in treating graft-versus-host disease (GVHD) in patients that have received allogenic bone marrow transplants.
    Type: Grant
    Filed: March 3, 1999
    Date of Patent: September 10, 2002
    Assignee: University of Southern California
    Inventor: David A. Horwitz
  • Patent number: 6432403
    Abstract: An antibody specific for the mammalian protein prenylcysteine carboxyl methyltransferase.
    Type: Grant
    Filed: November 8, 2000
    Date of Patent: August 13, 2002
    Assignee: New York University
    Inventor: Mark R. Philips
  • Patent number: 6416758
    Abstract: Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: July 9, 2002
    Assignee: Board of Regents, The University of Texax System
    Inventors: Philip E. Thorpe, Rolf A. Brekken
  • Patent number: 6416977
    Abstract: The present invention relates to flea chitinase nucleic acid molecules, proteins encoded by such nucleic acid molecules, antibodies raised against such proteins, and inhibitors of such proteins. The present invention also includes therapeutic compositions comprising such nucleic acid molecules, proteins, antibodies, and/or other inhibitors, as well as their use to protect an animal from flea infestation.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: July 9, 2002
    Assignee: Heska Corporation
    Inventor: Anna M. Becher
  • Patent number: 6410020
    Abstract: Monoclonal antibodies which have binding specificity to human CETP(CETP inhibition activity) and which are useful as reagents for purification or quantification of human CETP, and as pharmaceuticals to prevent and/or treat hyperlipidemia or arteriosclerosis are provided. Furthermore, purification and quantification methods of human CETP by using the monoclonal antibodies are also provided.
    Type: Grant
    Filed: July 12, 2000
    Date of Patent: June 25, 2002
    Assignee: Japan Tobacco, Inc.
    Inventors: Masafumi Kamada, Hiroshi Okamoto, Takuya Tamatani
  • Patent number: 6410708
    Abstract: The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer, and nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing such antigens PRO301, PRO362 or PRO245.
    Type: Grant
    Filed: March 5, 1999
    Date of Patent: June 25, 2002
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Sherman Fong, Audrey Goddard, Austin L. Gurney, Mary A. Napier, Daniel Tumas, William I. Wood
  • Patent number: 6407215
    Abstract: A substantially pure protein that is a member of the apoptotic Ced-3/Ice cysteine protease gene family, Mch2&agr;, and an inactive isoform of it, Mch2&bgr;, are disclosed. Isolated nucleic acid molecules that encode Mch2&agr; and Mch2&bgr;, respectively, are disclosed. Pharmaceutical compositions comprising a pharmaceutically acceptable carrier in combination with the protein or the nucleic acid molecules are disclosed. Fragments of nucleic acid molecules that encode Mch2&agr; and Mch2&bgr; having at least 10 nucleotides and oligonucleotide molecule comprising a nucleotide sequence complimentary to a nucleotide sequence of at least 10 nucleotides are disclosed. Recombinant expression vectors that comprise the nucleic acid molecule that encode Mch2&agr; or Mch2&bgr;, and host cells that comprise such recombinant vectors are disclosed. Antibodies that bind to an epitope on Mch2&agr; and/or Mch2&bgr; are disclosed. Methods of identifying inhibitors, activators and substrates of Mch2&agr; are disclosed.
    Type: Grant
    Filed: August 17, 1999
    Date of Patent: June 18, 2002
    Assignee: Thomas Jefferson University
    Inventors: Gerald Litwack, Emad S. Alnemri, Teresa Fernandez-Alnemri
  • Patent number: 6383484
    Abstract: The invention is based on the isolation of antibodies that were made to a polypeptide having the amino acid sequence for a truncated VEGF-D. One of these antibodies can interfere with the activity of VEGF-D mediated by VEGFR-2 and interfere with the binding of VEGF-D to VEGFR-3 but does not interfere with the activity of VEGF mediated by VEGFR-2 or bind to VEGF-C. The invention provides pharmaceutical and diagnostic compositions and methods utilizing these antibodies.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: May 7, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Marc G. Achen, Steven Alan Stacker
  • Patent number: 6379901
    Abstract: The invention involves a nonapeptide derived from the tumor rejection antigen precursor encoded by gene MAGE-3. This nonapeptide is presented by the HLA molecule HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: April 30, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurguin, Catia Traversari, Beatrice Gaugler, Benoit Van den Eynde
  • Patent number: 6362318
    Abstract: The subject of the invention is a new protein called EPIL or placentin, its analogs ing EPIL/placentin-type activity, obtained by deletion and/or substitution. The tion also concerns a DNA molecule coding for a EPIL/placentin-type polypeptide. It ly concerns a pharmaceutical composition containing EPIL/placentin or a /placentin analog.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: March 26, 2002
    Inventors: Ahmet Koman, Dorine Chassin, Dominique Bellet
  • Patent number: 6358489
    Abstract: Thiol-containing peptides can be radiolabeled with fluorine-18 (F-18) by reacting a peptide comprising a free thiol group with an F-18-bound labelling reagent which also has a group that is reactive with thiols. The resulting F-18-labeled peptides may be targeted to a tissue of interest using bispecific antibodies or bispecific antibody fragments having one arm specific for the F-18-labeled peptide or a low molecular weight hapten conjugated to the F-18-labeled peptide, and another arm specific to the targeted tissue. The targeted tissue is subsequently visualized by clinical positron emission tomography.
    Type: Grant
    Filed: August 24, 2000
    Date of Patent: March 19, 2002
    Assignee: Immunomedics, Inc.
    Inventor: Gary L. Griffiths